BiotechTube
FAScinate Therapeutics

FAScinate Therapeutics

Cambridge, United States· Est.
fascinatetherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $82.5M

Overview

FAScinate Therapeutics is a private, pre-revenue biotech founded in 2018, targeting a high-unmet need in neurodegenerative diseases with its lead asset, KM-819. The company's mission is to shift the treatment paradigm for conditions like Parkinson's disease from symptomatic management to disease modification. Operating from the biotech hub of Cambridge, MA, the company is in the clinical development stage and is actively seeking investment and development partnerships to advance its program.

Parkinson's DiseaseMultiple System AtrophyNeurodegenerative Diseases

Technology Platform

Small molecule platform targeting a unique mechanism to halt the progression of neurodegenerative diseases, potentially focused on protein homeostasis or neuronal survival pathways.

Funding History

3
Total raised:$82.5M
Series A$65M
Seed$5.5M
Seed$12M

Opportunities

The primary opportunity is addressing the massive, unmet need for disease-modifying therapies in Parkinson's disease, a multi-billion dollar market.
Success could also open the rare disease pathway in Multiple System Atrophy and provide proof-of-concept for expansion into other neurodegenerative indications.

Risk Factors

High risk of clinical failure inherent in neurodegenerative drug development, where many mechanisms fail to show efficacy.
Significant financing risk as a private, single-asset company, and intense competition from larger, better-resourced entities in the same therapeutic space.

Competitive Landscape

The landscape for disease-modifying Parkinson's therapies is highly competitive, involving large pharmaceutical companies and numerous biotechs targeting alpha-synuclein, inflammation, and other pathways. FAScinate must differentiate its mechanism and demonstrate superior or complementary efficacy to succeed.

More companies in Small Molecule Drugs →More companies in United States →